First Department of Critical Care, Medical School, University of Athens, Evangelismos Hospital, 45-47 Ipsilantou Str., 106 76, Athens, Greece.
Intensive Care Med. 2013 Jul;39(7):1253-61. doi: 10.1007/s00134-013-2914-z. Epub 2013 Apr 20.
Carbapenem-resistant (CR) Gram-negative pathogens have increased substantially. This study was performed to identify the risk factors for development of CR Gram-negative bacteremia (GNB) in intensive care unit (ICU) patients.
Prospective study; risk factors for development of CR-GNB were investigated using two groups of case patients: the first group consisted of patients who acquired carbapenem susceptible (CS) GNB and the second group included patients with CR-GNB. Both case groups were compared to a shared control group defined as patients without bacteremia, hospitalized in the ICU during the same period.
Eighty-five patients with CR- and 84 patients with CS-GNB were compared to 630 control patients, without bacteremia. Presence of VAP (OR 7.59, 95 % CI 4.54-12.69, p < 0.001) and additional intravascular devices (OR 3.69, 95 % CI 2.20-6.20, p < 0.001) were independently associated with CR-GNB. Presence of VAP (OR 2.93, 95 % CI 1.74-4.93, p < 0.001), presence of additional intravascular devices (OR 2.10, 95 % CI 1.23-3.60, p = 0.007) and SOFA score on ICU admission (OR 1.11, 95 % CI 1.03-1.20, p = 0.006) were independently associated with CS-GNB. The duration of exposure to carbapenems (OR 1.079, 95 % CI 1.022-1.139, p = 0.006) and colistin (OR 1.113, 95 % CI 1.046-1.184, p = 0.001) were independent risk factors for acquisition of CR-GNB. When the source of bacteremia was other than VAP, previous administration of carbapenems was the only factor related with the development of CR-GNB (OR 1.086, 95 % CI 1.003-1.177, p = 0.042).
Among ICU patients, VAP development and the presence of additional intravascular devices were the major risk factors for CR-GNB. In the absence of VAP, prior use of carbapenems was the only factor independently related to carbapenem resistance.
耐碳青霉烯类(CR)革兰氏阴性病原体的数量显著增加。本研究旨在确定重症监护病房(ICU)患者发生耐碳青霉烯类革兰氏阴性菌血症(GNB)的危险因素。
前瞻性研究;使用两组病例患者来研究发生耐碳青霉烯类-GNB 的危险因素:第一组包括获得耐碳青霉烯类敏感(CS)GNB 的患者,第二组包括耐碳青霉烯类-GNB 患者。将这两组病例组与同期无菌血症、在 ICU 住院的共享对照组进行比较。
将 85 例耐碳青霉烯类和 84 例耐碳青霉烯类 CS-GNB 患者与 630 例无菌血症对照患者进行比较。VAP(比值比 [OR] 7.59,95%置信区间 [CI] 4.54-12.69,p<0.001)和附加血管内装置(OR 3.69,95%CI 2.20-6.20,p<0.001)的存在与耐碳青霉烯类-GNB 独立相关。VAP 的存在(OR 2.93,95%CI 1.74-4.93,p<0.001)、附加血管内装置的存在(OR 2.10,95%CI 1.23-3.60,p=0.007)和 ICU 入院时 SOFA 评分(OR 1.11,95%CI 1.03-1.20,p=0.006)与耐碳青霉烯类 CS-GNB 独立相关。暴露于碳青霉烯类(OR 1.079,95%CI 1.022-1.139,p=0.006)和粘菌素(OR 1.113,95%CI 1.046-1.184,p=0.001)的时间与耐碳青霉烯类-GNB 的发生有关。当菌血症的来源不是 VAP 时,先前使用碳青霉烯类是与耐碳青霉烯类-GNB 发展相关的唯一因素(OR 1.086,95%CI 1.003-1.177,p=0.042)。
在 ICU 患者中,VAP 的发生和附加血管内装置的存在是耐碳青霉烯类-GNB 的主要危险因素。在没有 VAP 的情况下,先前使用碳青霉烯类是与碳青霉烯类耐药相关的唯一因素。